Antonio, I know that you saw asymmetric investing opportunity in $AMD especially when it was significantly undervalued years ago and was rewarded accordingly. One may argue valuation has caught up to $AMD since then, although recently whole semiconductor space has taken a beating. Given current climate with semiconductor business (China geopolitical tensions/ US Chip Act/ cyclical nature/ competitions such as $NVDA, $INTL), do you still feel that $AMD specifically is still the company with asymmetric investment upside? As opposed to $NVDA, $TSM, $ASML, etc.
Also, I know that $DNA was significantly overvalued when you reviewed them last year, but since then their valuation has significantly decreased, and they are still in a promising field with great financials ($2 billion cash run way, which is more comforting in current economic crisis), although not vertically integrated like $AMRS. Do you see any asymmetric upside in $DNA now?
Hey investorMD! Yes, I do feel like $AMD has a long way to go over the next 5-10 years. I will be posting my deep dive on the company next week.
About $DNA, my issue with the company was as you say valuation on one end and on the other, the fact that they can´t actually make things with their technology. I think the market brushes over the difficulty of manufacturing in syn bio. I have a second look at $DNA in my pipeline, so stay tuned.
Thanks Antonio. I agree that the vertical integration can be attractive - in the case of $TSLA and $AMRS. That said, in the case of semiconductors, $AMD and $NVDA only specialize in designing but not manufacturing their products, yet they are profitable, so it can seem a bit inconsistent when we look for the vertical integration. Will be looking forward to your DD's!
The difference between semis and syn bio is that in the latter, the methods of production are alive - so the design is an intrinsic part of the manufacturing and viceversa. Thanks, excited to share soon!
Cool post Antonio! Simple and valuable way to think about the world and investments.
Thanks a lot, Erik
Antonio, I know that you saw asymmetric investing opportunity in $AMD especially when it was significantly undervalued years ago and was rewarded accordingly. One may argue valuation has caught up to $AMD since then, although recently whole semiconductor space has taken a beating. Given current climate with semiconductor business (China geopolitical tensions/ US Chip Act/ cyclical nature/ competitions such as $NVDA, $INTL), do you still feel that $AMD specifically is still the company with asymmetric investment upside? As opposed to $NVDA, $TSM, $ASML, etc.
Also, I know that $DNA was significantly overvalued when you reviewed them last year, but since then their valuation has significantly decreased, and they are still in a promising field with great financials ($2 billion cash run way, which is more comforting in current economic crisis), although not vertically integrated like $AMRS. Do you see any asymmetric upside in $DNA now?
Hey investorMD! Yes, I do feel like $AMD has a long way to go over the next 5-10 years. I will be posting my deep dive on the company next week.
About $DNA, my issue with the company was as you say valuation on one end and on the other, the fact that they can´t actually make things with their technology. I think the market brushes over the difficulty of manufacturing in syn bio. I have a second look at $DNA in my pipeline, so stay tuned.
Thanks Antonio. I agree that the vertical integration can be attractive - in the case of $TSLA and $AMRS. That said, in the case of semiconductors, $AMD and $NVDA only specialize in designing but not manufacturing their products, yet they are profitable, so it can seem a bit inconsistent when we look for the vertical integration. Will be looking forward to your DD's!
The difference between semis and syn bio is that in the latter, the methods of production are alive - so the design is an intrinsic part of the manufacturing and viceversa. Thanks, excited to share soon!